S&P 500: 669.03 +1.0% NASDAQ 100: 600.38 +1.1% Dow Jones: 470.30 +0.8%

Steven Cohen’s KYMR Holdings & Trades

First Buy
Q2 2021
Duration Held
10 Quarters
Largest Add
Q1 2022
+594,600 Shares
Current Position
173,147 Shares
$13.47 M Value

Steven Cohen's KYMR Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 173,147 shares of Kymera Therapeutics, Inc. (KYMR) worth $13.47 M, representing 0.02% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 10 quarters.

Based on 13F filings, Steven Cohen has maintained a strategic position in KYMR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 594,600 shares. Largest reduction occurred in Q2 2022, reducing 652,800 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Kymera Therapeutics (KYMR) Holding Value Over Time

Track share changes against reported price movement

Quarterly Kymera Therapeutics (KYMR) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -753 Reduce 0.43% 173,147 $77.81
Q3 2025 -10,578 Reduce 5.73% 173,900 $56.60
Q2 2025 +184,478 New Buy 184,478 $43.64
Q4 2023 -81,400 Sold Out 0 $0.00
Q3 2023 +81,400 New Buy 81,400 $13.90
Q2 2022 -652,800 Sold Out 0 $0.00
Q1 2022 +594,600 Add 1021.65% 652,800 $42.32
Q4 2021 -99,200 Reduce 63.02% 58,200 $63.49
Q3 2021 +89,800 Add 132.84% 157,400 $58.74
Q2 2021 +67,600 New Buy 67,600 $48.51

Steven Cohen's Kymera Therapeutics Investment FAQs

Steven Cohen first purchased Kymera Therapeutics, Inc. (KYMR) in Q2 2021, acquiring 67,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Kymera Therapeutics, Inc. (KYMR) for 10 quarters since Q2 2021.

Steven Cohen's largest addition to Kymera Therapeutics, Inc. (KYMR) was in Q1 2022, adding 652,800 shares worth $27.63 M.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 173,147 shares of Kymera Therapeutics, Inc. (KYMR), valued at approximately $13.47 M.

As of the Q4 2025 filing, Kymera Therapeutics, Inc. (KYMR) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Kymera Therapeutics, Inc. (KYMR) was 652,800 shares, as reported at the end of Q1 2022.